Median Technologies strengthens its medical leadership with the appointment of Dr. Loan Hoang-Sayag as Chief Medical Officer and the appointment of Dr. Fabien Ricard as Medical Director, North America.
Press Release – For immediate release – 5:45PM CEST
- Dr. Loan Hoang-Sayag will lead the company’s global clinical vision and medical strategy and contribute to the overall strategic plan for the company.
- Dr. Fabien Ricard will manage Medical Affairs, supporting the company’s clinical trials operations and business development activities in North America.
Median Technologies, The Imaging Phenomics Company® (ALMDT:PA) announces the appointment of Dr. Loan Hoang-Sayag as Chief Medical Officer and the appointment of Dr. Fabien Ricard as Medical Director, North America.
As Chief Medical Officer of Median, Loan Hoang-Sayag, MD will oversee the global clinical vision and medical strategy of the company and will closely work with Median’s scientific advisors. She will support all company business segments on medical and regulatory aspects and provide a clinical perspective to all activities of the company.
Dr. Hoang-Sayag is board-certified in hematology and medical oncology from Necker-Paris V René Descartes University and St-Antoine- Paris VI University, respectively. Dr. Hoang-Sayag has over 25 years of hematology and oncology experience within the clinical and academic settings and over 17 years of experience leading oncology drug development.
Dr. Hoang-Sayag started her industry career at Hoffmann-La Roche where she was responsible for clinical development and medical affairs activities for different oncology drugs. Following this post, she held roles at both Pierre Fabre Oncology and Quintiles where she led oncology development programs and the European Oncology Medical team, respectively. Most recently, Dr. Hoang-Sayag served as the Chief Medical Officer at Cellectis.
Her drug development experience encompasses new chemotherapeutic entities, small molecules, monoclonal antibodies, antibody drug conjugates, stem cell therapy, checkpoint inhibitors, and CAR-T cell therapy.
“I am proud and honored to join Median, which has a truly innovative vision in the field of oncology and other disabling diseases, and as such, delivers new and powerful insights into personalized medicine,” said Dr Loan Hoang-Sayag.
As Medical Director, North America, Dr. Fabien Ricard will be responsible for managing Medical Affairs, supporting Median’s clinical trials operations and business development activities.
Fabien Ricard is an imaging specialist dual-trained in Radiology and Nuclear Medicine with more than 10 years of clinical practice. Dr. Ricard has more than 8 years of experience in the Medical and Pharmaceutical Industry for clinical trials in Europe, Canada and USA and is a researcher in the field of Biomedical Engineering focusing on imaging biomarkers.
Previously, Dr. Fabien Ricard served as associate Medical Director of Medical Imaging at Advance Medical and as a specialist MRI Reader at NeuroRx Research. Fabien earned his imaging MD and research MS degrees from the University of Lyon, France, where he specialized during his residency and clinical fellowship in advanced multimodal imaging for oncology and onco-hematology, and served as an active sub investigator and member of the Lymphoma Study Association LYSA.
“I am delighted to be working with the Median team and to be part of this dynamic and outstanding company combining innovation and passion to build a healthier world for patients. Improving patient care through innovative imaging in clinical trials is how we can change lives and bring hope to patients,” said Dr. Fabien Ricard.
“Innovation in healthcare is currently going through a major transformation driven by advances in artificial intelligence, cloud computing and cybersecurity. Medical imaging is playing an increasing role in drug development and precision medicine with the introduction of predictive and non-invasive biomarkers for the benefit of patients worldwide. I am extremely proud to have Loan and Fabien join us at Median. It underscores the commitment of Median to be at the forefront of clinical research and development through imaging biomarkers,” said Fredrik Brag, Chief Executive Officer of Median Technologies.
“We are thrilled to have Loan and Fabien join our team at Median. As industry experts, they are bringing with them significant medical, scientific and clinical product development expertise that will support our continued efforts to bring innovative and patient-driven products and services to the market in an expedited manner,” said Jeanne Hecht, Chief Operating Officer of Median Technologies.
About Median Technologies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for Patient Care, iSee® for image management in clinical trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2017-2018. Median Technologies has been awarded the 2017 Tech 40 Label, has joined the EnterNext Tech 40 Index and is a winner of the Deloitte Technology Fast 500™ 2017 EMEA program. Median is a member of the Bpifrance Excellence Network. For more information: www.mediantechnologies.com
VP, Head of Investor and Media Relations
+1 312 282 3923
+33 1 56 88 11 11
Alizé RP (Press)
+33 1 44 54 36 66